9 Results for "

bivalent hapten

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "bivalent hapten" in MCE Product Catalog:

Cat. No.: HY-155447
CAS No.: 136687-43-9
Target:  

Hapten

Research Areas:  

Cancer

AG3.0 is a symmetric di-HSG bivalent hapten. AG3.0 can be used for the research of pretargeted radioimmunotherapy .
loading...
    loading...
Cat. No.: HY-155469
CAS No.: 391267-27-9
Target:  

Hapten

Research Areas:  

Others

IMP 241 is a di-HSG bivalent hapten .
loading...
    loading...
Cat. No.: HY-155445
CAS No.: 136687-39-3
Target:  

Hapten

Research Areas:  

Cancer

di-DTPA TL is a hydrophilic bivalent DTPA hapten that can be used for tumor research .
loading...
    loading...
Cat. No.: HY-180435
CAS No.: 160037-48-9
Research Areas:  

Cancer

Janus-DOTA is a bivalent hapten, can be used for drug delivery .
loading...
    loading...
Cat. No.: HY-155444
Target:  

Histamine Receptor

Research Areas:  

Cancer

AG5.0 is a bivalent hapten contains one HSG (histamine-succinyl-glycyl) group and one DTPA-indium group .
loading...
    loading...
Cat. No.: HY-155468
CAS No.: 159173-58-7
Research Areas:  

Others

AG8.0 is a symmetric di-HSG bivalent hapten. AG8.0 is stable in vivo for 24 h .
loading...
    loading...
Cat. No.: HY-155471
CAS No.: 608489-42-5
Research Areas:  

Others

IMP 245 is a symmetric di-HSG bivalent hapten. IMP 245 has low toxicity, high affinity binding to available antibodies and absence of cross reactivity or non-specific binding with body components .
loading...
    loading...
Cat. No.: HY-155470
CAS No.: 391267-29-1
Research Areas:  

Cancer

IMP 243 is a symmetric di-HSG (histamine-succinyl-glycine) bivalent hapten containing a Tscg-Cys ligand and two HSG groups. IMP 243 can be radiolabeled with 99mTc-pertechnetate. IMP 243 can be conjugated to other peptides to design bispecific antibodies (bsMAbs) for cancer research .
loading...
    loading...
Cat. No.: HY-155446
Target:  

Hapten

Research Areas:  

Inflammation/Immunology Cancer

di-DTPA-LTL is a bivalent hapten based on tyrosine-containing polypeptide design. di-DTPA-LTL has good hydrophilia and biological distribution. di-DTPA-LTL is labeled with 111In (indium) and 131I (iodine). di-DTPA-LTL achieves tumor radioimmunoimaging in primary colorectal cancer patients with CEA by injecting a fixed low dose (5 mg) of bispecific antibody (anti-CEA x, anti-DTPA) and di-DTPA antigen peptide (labeled 111In) into the patients .
loading...
    loading...